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Abstract
Background: Asthma and allergy are highly prevalent in industrialised countries. Longitudinal and
cross-sectional studies have identified a number of potential risk factors for these conditions,
including genetic and environmental factors, with significant gene-environment relationships. Birth
cohort studies have been proposed as an important tool to explore these risk factors, particularly
exposures in early life that are associated with later disease or protection from disease. This paper
describes the establishment of a birth cohort in New Zealand.
Methods: A birth cohort was established in 1996 in Christchurch and Wellington and infants
recruited between 1997–2001. Expectant mothers were recruited by midwives. Children and
mothers have undergone assessment by serial questionnaires, environmental assessment including
mould and allergen exposure, skin-prick testing, and at age six years are undergoing full assessment
for the presence of asthma, atopy and allergic disease, including genetic assessment.
Results: A total of 1105 children have been recruited, and the retention rate at fifteen months was
91.4%. 15.2% of the children at recruitment have been identified as Maori. A positive family history
of asthma, eczema or hay fever has been reported in 84% of children. All children have now been
assessed at fifteen months and 685 children from the cohort have reached age six years and have
completed the six year assessment.
Conclusion: The cohort is fully assembled, and assessment of children is well advanced, with good
retention rates. The study is well placed to address many current hypotheses about the risk factors
for allergic disease and asthma.
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Background
The incidence of atopy, allergic disease and asthma is
increasing in industrialised nations, including New Zea-
land. Longitudinal birth cohorts such as in Tucson USA
[1] Melbourne [2] and Perth [3] Australia, and the Ger-
man multi-centre atopy study (MAS-90) [4], as well as
cross-sectional studies such as Belmont [5] in Australia
have identified a number of potential risk factors for the
development of atopy, allergic disease and asthma. These
include a genetic predisposition, foetal growth [6] and a
variety of early life environmental factors.
Exposure to house dust mite allergens is strongly associ-
ated with sensitisation [7], and in turn sensitisation is
strongly associated with asthma [8]. The relationships
between allergen exposure and the development of
asthma appear more complex [9]. New Zealand has
amongst the highest levels of house dust mite allergen in
the world, and is therefore well placed to further explore
such relationships. Although a birth cohort established 34
years ago in Dunedin has reported on determinants of
asthma and atopy [8,10], early life exposure information
from this cohort is sparse, preventing detailed examina-
tion of current hypotheses.
This paper describes the establishment of a New Zealand
birth cohort, to explore environmental and genetic factors
associated with the development of atopy, allergic disease
and asthma. Specifically we wished to explore the influ-
ence of perinatal factors, anthropometric measurements,
infant infections, family size, immunisation, diet, envi-
ronmental allergen and environmental tobacco smoke
exposure on the development of atopy, allergic disease
and asthma. There are a number of reasons for mounting
such a study in New Zealand, including high prevalence of
allergic disease and asthma, high allergen levels, and low
industrial pollution levels. In addition, the New Zealand
population has been extensively studied in the context of
other international work [11,12], allowing comparisons
with previous studies to be undertaken. There is growing
recognition of the importance of longitudinal birth stud-
ies in trying to understand the true progression of asthma
and atopic disease and to identify risk factors [13]. Equally
it is important to recognise their limitations and to docu-
ment the assembly and investigation of birth cohorts. This
has also recently been recognised by the publication of the
study designs of asthma and allergic disease birth cohorts
in Europe [14].
In this paper we have therefore summarised the assembly
and study of a birth cohort of infants in New Zealand to
age eight years.
Methods
A prospective birth cohort of 1000 infants born in two
metropolitan centres (Christchurch, population 417,000,
and Wellington, population 420,000) in New Zealand
was established in 1997. Planning for the study started in
1996. The two centres were chosen because there were
established respiratory research organisations in both cit-
ies, and the requirements for large numbers of infants and
potential recruitment challenges necessitated two-centre
recruitment. Details of the timeline for all assessments are
given in Table 1.
Mothers and infants were recruited through midwives
between 1997–2000 in Wellington and 1998–2001 in
Christchurch. Expectant mothers were approached by
their midwives to give written informed consent to be
enrolled in the study prior to delivery. Midwives were
selected randomly from all midwives practising in Wel-
lington and Christchurch and were trained and supported
by trial coordinators. Midwives were encouraged to dis-
cuss the study and try and enrol all expectant mothers
under their care, to reduce selection bias. No explicit
attempt was made to recruit families with a history of
atopy, allergic disease or asthma, indeed the importance
of enrolling all mothers was stressed. There were no
explicit exclusion criteria in the peri-natal period; in par-
ticular non-singleton pregnancies were able to be
included. Midwives were asked to keep a record of all
mothers that they approached and to collect basic demo-
graphic information on them in particular mothers who
declined to participate. In addition, efforts were made to
ensure Maori participation by ongoing contact with Maori
health providers and consumer groups. All mothers gave
written informed consent for their children to participate
in this study to monitor their health and development
and undergo regular assessments in the form of inter-
views, questionnaires and a variety of specific tests. The
initial informed consent process covered assessments for
the first five years, with subsequent consent for the six and
eight year assessments being obtained prior to these
assessments (including consent for DNA collection, stor-
age and genetic analysis-see below). Verbal agreement was
obtained from each child prior to the six and eight year
assessments, as required by our local ethics committees; if
a child refused any particular segment, this was not under-
taken.
All assessments were administered by trained research
staff, using a pre-agreed manual of procedures. Extensive
pre-testing of assessment procedures undertaken on non-
participant families prior to use, and ongoing inter-centre
quality control of assessments and staff was undertaken
through the study.BMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
Page 3 of 9
(page number not for citation purposes)
Ethics committee approval for the conduct of the study
was obtained from the Wellington and Canterbury
Regional Ethics Committees.
In 1993 and 1994 a pilot study of 154 new born infants
was undertaken in Wellington [15]. These children were
followed with visits at 15 months and 6 years. This pilot
provided insights into the design and practical problems
associated with large cohort studies, in particular prob-
lems with the skin prick testing. There was an initial
response rate of over 90% with a 15 months follow-up
rate of 97%.
The statistical rationale behind a cohort of 1000 children
was based on this pilot data for the major risk factors, and
the prevalence of asthma was based on New Zealand
research available at the time. At 15 months, with a fol-
low-up rate of 90%, a prevalence of atopy of 20%, a prev-
alence of the major risk factors of 20% (e.g. high house
dust mite exposure) the study will have 95% power to
detect a relative risk of atopy of 1.7. At 6 years, with a fol-
low-up rate of 75%, a 12 month period prevalence of
asthma symptoms or atopy of 20%, a prevalence of the
major risk factors of 20%, the study will have >90% power
to detect a relative risk of 1.7. These assumptions are con-
servative and are in keeping with the findings of the
ISAAC study, which found the prevalence of asthma
symptoms in six-to seven-year old children to be 25%
[11]. Furthermore our follow-up rate at 6 years is greater
than the 75% predicted.
Assessments and data acquisition
Questionnaires
All questionnaires have been informed by previous New
Zealand studies [8,11], together with new questions
addressing specific hypotheses.
Recruitment visit
Expectant mothers were recruited into the study by partic-
ipating midwives and consent for participation was con-
firmed soon after birth by the study team.
Birth
At birth, midwives or study nurses collected data about
the birth including any complications. Anthropometric
details were collected including birth weight, length and
Table 1: Investigation Timeline
Recruitment/Birth 3 Months 6 Months 15 Months 2 Years 3 Years 4 Years 5 Years 6 Years 8 Years
QUESTIONNAIRE
Birth Details/Parity x
Diet/Feeding Practices x x x x x
Family Health
-Parental Health x xx
- S i b l i n g s  H e a l t h x x xxxxxx
Outcome Measures
- A s t h m a  &  A t o p y x x xxxxxx
- M e d i c a t i o n  U s e x x xxxxxx
- H e a l t h c a r e  C o n t a c t s x x xxxxxx
- I n f e c t i o n s / I l l n e s s e s x x xxxxx
Allergen Avoidance xx
V a c c i n a t i o n s x x xxxxxx
I n d o o r  E n v i r o n m e n t x x xxxxxx
S m o k i n g x x xxxx
Childcare xx x
Exercise & Activity x
Indoor Swimming Pools x
OBJECTIVE MEASURES
Anthropometry x x x x
Cord Blood Collection x
Dust Collection
-Childs bedroom floor x x
-Childs bed x x
Skin Prick Testing x x
Spirometry x
Exhaled Nitric Oxide x
Nitrogen Dioxide (home) x




Anthropometry xBMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
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head circumference. Cord blood was collected by the mid-
wife for measurement of IgE.
A face to face questionnaire interview was administered
including demographic details, initial feeding practices,
delivery details, infant's health status, and medications
(including Vitamin K).
Three month home visit
A face to face questionnaire was administered to collect
information about ethnicity (parental-identification of
child's ethnicity as recommended by the Population Cen-
sus in New Zealand), family details, occupation and
socio-economic status, breast- and/or formula-feeding
practices, introduction of solid foods, and diet, child's
health and vaccinations, medications, indoor environ-
ment, smoking, and child care.
Indoor dust samples were taken from child's bedding and
bedroom floor for measurement of the house dust mite
and cat allergens Der p 1 and Fel d 1, endotoxin, peptidog-
lycans and beta glucans as a marker of fungal biomass. A
Hitachi CV-2500 vacuum cleaner (1100 W) was used for
vacuuming, with the dust collected using a 25 μm pore
nylon mesh sock. In the bed, an area of 0.25 square meters
was vacuumed for two minutes, on the item that was
immediately below the blanket/sheet the child slept on.
On the bedroom floor, an area of one square meter was
vacuumed for one minute on carpet or rugs, or for two
minutes on bare floorboards. The samples were labelled
and placed in plastic bags, and then stored at -20°C until
they were sifted and analysed. Der p 1 and Fel d 1 were
analysed by ELISA [16,17]. Endotoxin was measured by
kinetic chromogenic Limulus Amoebocyte Lysate (LAL)
method (Bio Whittaker, Walkersville, MD, USA). A meas-
ure of peptidoglycan exposure was determined by quanti-
fying muramic acid levels present in house-dust samples
using ion-trap gas chromatography-tandem mass spec-
trometry (GC-MS-MS) [18]. Beta glucans will be quanti-
fied using ELISA [19].
The child's mother reported the presence of damp and
mould, including a damp or musty smell in the whole
house. This data was also collected for the child's bed-
room by the interviewer [20].
Six month telephone questionnaire
A questionnaire to collect information about feeding
practices, introduction of solid foods, and diet.
Fifteen month home visit
A comprehensive health questionnaire was administered
as at three months including a full dietary questionnaire
covering breast- and/or formula-feeding practices over the
previous twelve months, current feeding practice, general
eating pattern and the consumption frequency of selected
foods.
Anthropometric measurements were taken including
height, weight, head circumference, and upper arm cir-
cumference. Maternal height and weight was also meas-
ured.
Skin prick tests were performed using the following aller-
gens; Dermatophagoides pteronyssinus, Cat, Dog, Rye Grass,
Cow's milk, Egg white, Peanut, Aspergillus, Cockroach,
Histamine, Negative control. We used the Quintest™ sys-
tem (Bayer Corporation, West Haven, CT) for skin prick
testing [21], having found difficulty in using the standard
methodology in 15 month old infants during the pilot.
The Quintest has five lancets per device which allows for
quick administration of the test. The devices were dipped
in a tray carrying ten of the allergens and then applied to
the child's back in quick succession. Two Quintest devices
were used and one test (dog) was done separately using a
single lancet. After fifteen minutes, wheals were measured
using standard techniques and the average of the perpen-
dicular diameters calculated. A positive allergen response
will be defined as an allergen to histamine ratio of > 0.5,
after subtraction of the negative control, and atopy
defined as at least one positive response [22].
Further collections of dust from bed and bedroom floor
were undertaken (see above), allowing comparisons of
allergen and endotoxin levels between three and fifteen
month assessments.
Two, three, four and five-year telephone questionnaires
Telephone questionnaires were subsequently undertaken
at two, three, four and five years. These questionnaires
covered family health, respiratory problems, health serv-
ice utilisation, dietary intake, vaccinations, indoor envi-
ronment, and childcare. In addition, in the four- and five-
year questionnaires we included questions updating envi-
ronmental tobacco smoke exposure, types of bedding
used by children, exposure to pets, and paracetamol use.
Six-year assessment
The extensive six-year assessment is currently being under-
taken on children in the cohort at the Wellington and
Christchurch research centres and is focussed on a
detailed enquiry about risk factors and obtaining a
number of objective markers of asthma and atopy. This
assessment includes the following investigations:
Questionnaire
The questionnaire, which has questions on outcome
measures largely taken from the ISAAC Phase II question-
naire, is designed for completion by the parent of the
child. It includes questions about the following: theBMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
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occurrence and severity of respiratory and atopic symp-
toms; presence of asthma and atopy; infections; health-
care contacts; medication usage (including paracetamol
and antibiotics); vaccination history; swimming pool vis-
its; diet and physical activity; family size; family history of
atopic diseases; and the indoor environment including:
environmental tobacco smoke exposure (with additional
questions exploring duration of exposure from birth),
bedding, pets, crowding, dampness and mould, cooking
and heating fuels.
Anthropometry
Anthropometry protocols are based on the Australian
Food and Nutrition Monitoring Unit (AFNMU) Expert
Panel Guidelines (2001) adapted from the measurement
protocol described by the World Health Organisation
(WHO Expert Committee 1995). Height is assessed using
a stadiometer (Wellington: GPM, SibnerHegner, Zurich,
Switzerland; Christchurch: KaWe Medizintechnik, Asperg,
Germany). Weight is assessed using Tanita HD-316 digital
scales (Tanita, Tokyo, Japan).
Exhaled Nitric Oxide
This is being measured, using a Niox® chemiluminescence
analyser (Aerocrine AB, Stockholm, Sweden), to ATS
standards [23] prior to the child undertaking any forced
expiratory manoeuvres. Quality control protocols and
reproducibility testing between investigators ensure valid
and acceptable results.
Spirometry
Resting spirometry is being undertaken to ATS standards
[24], using a Vitalograph Pneumotrac 6800 Fleisch-type
Pneumotachograph and Spirotrac IV software (version
4.20) (Vitalograph, Buckingham, England). Bronchodila-
tor reversibility is also being undertaken on all children
fifteen minutes following the administration of inhaled
salbutamol 200 μg using a Volumatic™ spacer (Allen and
Hanburys Ltd, UK). All spirometry is being undertaken by
trained research staff in research laboratories. Within cen-
tre calibration biological control programmes ensure
technically acceptable and reproducible spirometry.
Skin Prick Testing
Skin prick testing is being undertaken to the following
allergens (Dome/Hollister-Stier, Spokane, WA): Dermat-
ophagoides pteronyssinus, perennial rye grass, olive tree
(Olea europaea), cat pelt, dog hair (dander), horse hair,
cockroach mix (american, german), egg white, peanut mix
(runner, virginia, spanish), cow's milk (whole), Aspergillus
fumigatus and Alternaria tenuiis. Positive control (Hista-
mine 10%) and negative control are also performed.
Because of problems associated with the Quintest (See
Discussion) we adopted a more traditional methodology
with allergens being applied to the volar aspects of both
forearms with a wooden applicator. Vertical punctures are
then made using individual stainless-steel lancets (Dome/
Hollister-Stier, Spokane, WA). Positive control is meas-
ured at ten minutes, and all other wheals measured at fif-
teen minutes [25], with wheals traced using a fine-tip pen.
A permanent record is transferred to the results booklet
using Micropore™ tape (3 M Healthcare, Saint Paul, MN).
Mean wheal diameter is measured using both the longest
and orthogonal diameters, recorded to the nearest 0.5
mm. A positive reaction is defined as a mean wheal diam-
eter of 3 mm or greater to any allergen, with atopy defined
as any positive reaction.
Observer internal-consistency and inter-observer variabil-
ity are both monitored within and between centres. Coef-
ficients of variation in histamine wheal size for each
investigator are required to be less than 0.2; this is tracked
throughout the study and addressed with retraining where
disparate.
Children are asked to refrain from medications and caf-
feine-containing drinks according to a protocol sent to the
mothers prior to the visit. The only exception is antihista-
mines where we ask the child to return if there is no
response to histamine on skin prick testing. The timing of
all medications taken prior to the visit is recorded.
Assessment of Atopic Dermatitis
This is being undertaken using the UK Atopic Dermatitis
Diagnostic Criteria Working Party protocol [26], includ-
ing a series of standardised questions and visual inspec-
tion for the presence of visible flexural dermatitis. The
examination involves inspection of the skin around the
eyes, around the sides and front of the neck, in front of the
elbows, behind the knees, and in front of the ankles. The
presence or absence of signs of visible flexural dermatitis
is recorded for each of the five areas. Standardisation is
ensured through the incorporated training certification
process, which includes a photographic observer's manual
containing high-quality clinical photographs.
Blood Samples
Blood samples are being collected by venepuncture, with
topical anaesthesia applied prior to venepuncture in all
children.
10 mL of serum is frozen and stored initially at -20°C, and
then transferred into -80°C for longer-term storage.
Serum will be analysed for total IgE levels and allergen-
specific antibody levels using CAP FEIA (Pharmacia Diag-
nostics, Uppsala, Sweden). Further aliquots are being ana-
lysed for strain-specific antibodies against currently
circulating strains of Respiratory Syncytial Virus (RSV),BMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
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subtypes A and B by an enzyme linked immunosorbent
assay (ELISA).
12 mL of whole blood is also collected as part of the same
venepuncture into EDTA sample tubes for Selenium anal-
ysis and DNA extraction.
Selenium Analysis
4 mL of whole blood is frozen immediately after
venepuncture to -20°C for glutathione peroxidase
(GSHPx) analysis. A further 4 mL, for selenium analysis,
is centrifuged (2,000 revolutions per minute for 10 min)
and aliquoted into a 2 mL microcentrifuge tube. This
plasma is then immediately frozen after separation.
Plasma selenium is determined by graphite furnace
atomic absorption spectrophotometry, using a modified
version of the method of Jacobson and Lockitch [27].
Samples are analysed in duplicate using a Perkin-Elmer
Model 3100 atomic absorption spectrometer (Perkin-
Elmer Corp., 761 Main Avenue, Norwalk, Connecticut
06859-0001).
Whole blood GSHPx is analysed using a Cobas Fara auto-
analyser with a modified version [28] of the method of
Paglia and Valentine [29]. A stock sample of whole blood
is analysed during each GSHPx run, as an internal biolog-
ical control.
DNA Extraction
The remaining 4 mL EDTA tube is immediately chilled to
4°C for subsequent DNA extraction and storage. In addi-
tion to the blood sample for DNA extraction, a buccal
DNA specimen is being collected as a contingency, or in
the event that venepuncture is not possible. This is col-
lected using an Endoscan plus cytology brush by brushing
the buccal mucosa for 15 seconds each side. The tip of the
brush is then cut and placed into a 2 mL cryovial contain-
ing 50 mM genomic quality sodium hydroxide (0.1 g in
50 mL molecularly pure water). This is then immediately
vortexed for 20 seconds and the brush tip discarded. The
specimen is then immediately frozen initially to -20°C
then transferred for longer-term storage at -80°C.
Genomic DNA will be extracted from buccal samples
using the method described by Richards and co-workers
[30].
Hair Nicotine
A hair sample (2–5 mg) is being collected and will be
assayed for nicotine to objectively assess personal expo-
sure to environmental tobacco smoke, using reversed-
phase high-performance liquid chromatography (HPLC)
with electrochemical detection [31].
Nitrogen Dioxide exposure
There is growing concern in New Zealand about the
health problems associated with poor housing, in partic-
ular cold and dampness. We have shown that 30% of New
Zealand households use unflued bottled gas heaters to
heat their homes [32]. These heaters are a significant
source of nitrogen dioxide, which has been associated
with increased asthma morbidity. A Nitrogen Dioxide
passive diffusion (Palmes) tube (Gradko International
Ltd, Hampshire, UK) is placed in a standardised location
in each child's home for 14 days following the child's
assessment [33].
Eight-year questionnaire
Largely similar to the six-year questionnaire this will col-
lect information on the major outcome measures and key
risk factors, including indoor environment.
Data Management
Data entry is completed separately by each centre, and the
data is subsequently cleaned and merged for analysis. A
single database has been generated, with the final copy
held at one centre only. Data is being analysed on an on-
going basis, in particular the analysis of early data to 15
months is well underway.
Results
The demographics of the cohort are shown in Table 2. A
total of 1105 children were recruited. The retention rate at
three months was 96.3% and at fifteen months was
91.4%. As of April 2006, a total of 421 children have
reached age six years, and have undergone the six-year
assessment in Wellington; 264 children have been
assessed in Christchurch (which started recruitment later
and will finish six-year assessment in 2007). 127 children
have to date completed the eight-year questionnaire in
Wellington. 15.2% of the children at recruitment have
been identified as Maori. A positive family history of
asthma, eczema or hay fever has been identified in 84% of
children.
The gender ratio in the cohort is 561:544 (50.8%:49.2%)
(Male:Female), with 45.9% being first-born, 35.5% being
second-born, and 18.6% being third-born or higher.
Maternal age ranges from 15.5 years to 46.7 years.
Discussion and Conclusion
Cohort studies always present a considerable challenge to
recruit and retain a representative sample of a population.
We have assembled a population based birth cohort of
over 1000 children in Wellington and Christchurch with
good retention rates. We specifically sought to obtain a
representative population sample rather than to recruit
families with a history of atopy, allergic disease or asthma
in order to provide greater generalisability of the results.BMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
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We were reliant on midwives for recruitment of mothers
in their care. We randomly sampled midwives from a vari-
ety of maternity care facilities including local hospital
birthing units, secondary care facilities and a number of
independent midwife practices. We met with the mid-
wives regularly and asked them to approach all mothers in
their care and to keep a record of all mothers that declined
to participate. This proved very difficult in practice and we
have no reliable information on how many mothers
declined, although we believe that in almost all cases mid-
wives did approach all mothers in their care. We are con-
fident however that the cohort sample is largely
representative of the wider New Zealand population,
based upon our comparisons with national demographic
statistics. For example, in the NZ Census of Populations
and Households 2001, 14.7% of the population identi-
fied as Maori. Overall, in Christchurch and Wellington,
15.2% of the cohort children have been identified as
Maori. Also parity in the cohort is not dissimilar from the
NZ National Statistics [34]. We had a slightly higher pro-
portion of 1st born children (46% cf 41% nationally), the
same proportion of second born children (36%), and a
slightly lower proportion of children with higher sibships
(19% cf 24% nationally). The national statistics were
based on births within marriages which may explain the
difference. Recent birth cohort studies have tended to
recruit from University or academic teaching hospitals
where high risk pregnancies or deliveries are likely to be
over represented and may therefore differ from the gen-
eral population. The issues raised by non-random sam-
pling for these birth cohorts are discussed by Keil and co-
workers who review recent European asthma and allergy
birth cohort studies as part of the GA2LEN (Global Allergy
and Asthma European Network) initiative. [14].
Another concern in cohort assembly is participation bias,
the inevitable increased participation of subjects who
have a family history of the conditions being studied. This
cannot be prevented but the extent to which it is present
can be assessed by collecting information on non-
responders and those not wishing to take part. In assem-
bling this cohort such information was not available for
the reasons discussed above. To assess participation bias
we have compared a family history of asthma, eczema or
hay fever amongst the cohort infants with the participants
in the Dunedin multidisciplinary cohort study [8]. We
defined family history as either parent having a history of
asthma, eczema or hayfever. Using this definition in the
most recent round of the Dunedin study (response rate
96%), when subjects were aged 32 years, (similar to the
average age of mothers in our cohort) 70% of female
cohort members reported a history of one or more allergic
diseases and 64% of males, (personal communication Dr
R. Hancox, Deputy Director, Dunedin Multi-disciplinary
cohort study) showing that 89% of random pairs of the
Dunedin cohort would have a history of allergic disease.
This suggests that our cohort is a reasonably unbiased
sample with no obvious evidence of participation bias
due to a family history of allergic disease.
The initial decision to use the Quintest equipment for the
fifteen-month skin test was made after initial piloting sug-
Table 2: Demographics of the New Zealand Asthma and Allergy Cohort
Christchurch Wellington Total
Total number of children recruited 552 553 1105
Total number with 3 month 
questionnaire data
535 (96.9%) 529 (95.7%) 1064 (96.3%)
Total number with 15 month 
questionnaire data
505 (91.4%) 506 (91.5%) 1011 (91.4%)
Male:Female (ratio %) 283:269 (51.3:48.7) 278:275 (50.3:49.7) 561:544 (50.8:49.2)
First born 41.3% 50.5% 45.9%
Second born 37.0% 34.0% 35.5%
Third + born 21.7% 15.6% 18.6%
Number of multiple births 10 2 12
Gestation: Mean (range) 39.6 (33.0–43.0) 39.6 (32.0–43.0) 39.6 (32.0–43.0)
Maternal age at birth: Mean (range) 29.9 (16.3–46.7) 30.3 (15.5–45.6) 30.1 (15.5–46.7)
Percentage Maori Children† * 11.6% 18.9% 15.2%
Percentage with Maori Mother * 5.6% 9.4% 7.5%
Family history† § n = 1046 85.2% 82.9% 84.0%
Smoking during pregnancy † 21.1% 20.8% 21.0%
Household smoking † 33.6% 31.8% 32.7%
Cord blood obtained 91.7% 87.5% 89.6%
† Collected at age 3 months
* Maori has been defined to include both sole Maori and Maori plus other ethnicity, using questions derived from the 1996 New Zealand Census.
§Family history has been defined to include either parent with asthma, hayfever or eczema. Fathers not living with the child were not asked this 
questionBMC Public Health 2007, 7:26 http://www.biomedcentral.com/1471-2458/7/26
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gested difficulties in performing SPT's using standard
prick methods in 15 month old infants. It was considered
that the Quintest would offer a number of advantages
including ease of administration, reducing distress
because of quicker testing times; standardisation of tech-
nique; less effect from child movement, and the simulta-
neous completion of all tests. During the course of the
study however we became concerned that the Quintests
were producing smaller wheals than would have been
expected using standard techniques. In 2000, we con-
ducted a study to examine the Quintest and compare it to
a standard prick-through application. Not only did we
confirm smaller wheal sizes from the Quintest, amongst
atopic adults, but we also we showed that this would lead
to a 25% misclassification of atopic status, when using a
mean wheal diameter of 3 mm as a cut off [35]. The Quin-
test also tended to produce more positive responses to the
negative control. We also found that there were significant
differences between two commonly used sources of com-
mercial allergen preparations, with allergens from one
source consistently producing smaller wheals regardless
of the methods used to apply them. Once again the source
of allergens also led to a 25% misclassification of atopy.
In order to reduce the impact of the smaller wheal sizes
from the Quintest we have used the histamine to wheal
ratio to define atopy. Thus for each allergen after subtrac-
tion of the negative control, atopy was defined as a hista-
mine allergen ratio ≥0.5. This ratio assessment has been
recommended by a number of investigators particularly in
young children [22] and reduces the impact of smaller
wheal sizes due to the Quintest device. It is important to
recognise that the assessment of atopic status in infancy
and early childhood can only ever be a partial assessment.
Many children will exhibit transient food sensitisation
and many others will not yet have developed sensitivity to
environmental allergens.
A number of birth cohorts have been established interna-
tionally to study a wide variety of factors associated with
the development of atopy, allergic disease and asthma
[14]. Given the recent hypotheses that the development of
these conditions involves a complex interaction between
genetic factors, and timing and magnitude of different
environmental factors, there are significant advantages to
investigators sharing testing protocols and information at
early stages, in order to test hypotheses under different
environmental conditions. The GA(2)LEN project funded
by the European Union is an example of this approach.
The high prevalence of allergic disease and asthma in New
Zealand, with high allergen levels and low industrial pol-
lution levels, allows testing of hypotheses generated by
both cross-sectional and longitudinal studies in a unique
environment. We present information about our cohort
to contribute to this process and encourage interested
researchers to contact the corresponding author for fur-
ther information.
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